News bites
EC probes J&J and Novartis
The European Commission has launched another antitrust investigation, this time examining whether contracts between Johnson
& Johnson and Novartis were designed to delay the market entry of generic versions of Fentanyl in the Netherlands.
Read more at:
http://www.PharmTech.com/ecprobe
GSK's US settlement
GlaxoSmithKline has come to a tentative agreement with the US government to conclude ongoing investigations relating to sales
and marketing practices. The settlement is still subject to negotiation, but GSK expects to pay around $3 billion, which is
covered by existing legal provisions.
Read more at:
http://www.PharmTech.com/gsksettles
Lily–Amyline alliance ends
Eli Lilly and Amylin have terminated their alliance relating to the diabetes medication exenatide. Amylin will have responsibility
for exanatide's global development and commercialisation while Eli Lilly will receive an upfront payment of $250 million and
a secured note for $1.2 billion plus interest.
Read more at:
http://www.PharmTech.com/lillyamylin
Annex 16 revisions
The EMA has released a concept paper for consultation that recommends a revision to Annex 16 of the Guide to Good Manufacturing
of Medicinal Products. According to the EMA, the revision will address new falsified medicines legislation and the industry's
complicated global supply chains.
Read more at:
http://www.PharmTech.com/annex16
|
